Patent · US Active

Use of modified cells for the treatment of multiple sclerosis

US9260692B2 · kind B2 · utility

22Cited by

1References

19Claims

0Family size

Assignee

Universitat Zurich · CH

Inventors

Roland Martin · Hamburg, DE
Andreas Lutterotti · Mils, AT

Key dates

Filing date	Mar 18, 2014
Grant date	Feb 16, 2016
Priority date	—
Expiry date	Aug 21, 2034

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2239/38
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention describes blood cells chemically coupled with immunodominant myelin peptides and their use in the treatment of Multiple Sclerosis.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.